First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197.
Elsa De la CadenaMaría Fernanda MojicaLaura J RojasBetsy E CastroJuan Carlos García-BetancurSteven H MarshallNatalia RestrepoNancy Patricia Castro-CaroMagalis Fonseca-CarrilloChristian PallaresRobert A BonomoMaría Virginia VillegasPublished in: Microbiology spectrum (2024)
carbapenemase (KPC) have established ceftazidime-avibactam (CZA) as an essential antimicrobial for the treatment of infections due to MDR Gram-negative pathogens. Although other countries in the region have reported the emergence of CZA-resistant KPC variants, this is the first description of such enzymes in Colombia. This finding warrants active surveillance, as dissemination of these variants could have devastating public health consequences.